RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0

作者：

Nakahara, Yoshiro ^{[1
]}

Hosomi, Yukio ^{[1
]}

Yomota, Makiko ^{[1
]}

Okuma, Yusuke ^{[1
]}

Takagi, Yusuke ^{[1
]}

Iguchi, Mari ^{[1
]}

Okamura, Tatsuru ^{[1
]}

机构：

[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期

关键词：

wild-type EGFR; Erlotinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2-034

引用

页码：S490 / S490

页数：1

共 50 条

[21] Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type EGFR (TORG1320).
Hosokawa, Shinobu
Bessho, Akihiro
Otani, Sakiko
Sasaki, Jiichiro
Igawa, Satoshi
Nakahara, Yoshiro
Fukamatsu, Nobuaki
Kasai, Takashi
Sugiyama, Tomohide
Seki, Nobuhiko
Nakamura, Yukiko
Tokito, Takaaki
Masuda, Noriyuki
Watanabe, Koshiro
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[22] Mechanism of epithelial-mesenchymal transition in erlotinib resistance in NSCLC cells containing both wild-type and mutant EGFR
Singh, Sanjana
Iderzorig, Tsatsral
Kumar, Pragya
Puri, Neelu
CANCER RESEARCH, 2018, 78 (13)
[23] CNS outcomes in EGFR/ALK wild-type NSCLC patients with brain metastases treated with immune checkpoint inhibitors (ICI).
Shultz, David Benjamin
Lau, Sally Cm
Poletes, Christopher
Le, Lisa W.
MacKay, Kate
Shepherd, Frances A.
Bradbury, Penelope Ann
Leighl, Natasha B.
Liu, Geoffrey
Sacher, Adrian G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Erlotinib in EGFR wild type platinum resistant NSCLC: now a predictor factor
Orlandi, A.
Di Salvatore, M.
Mannavola, F.
Calegari, M. A.
Inno, A.
Bagala, C.
Cassano, A.
Astone, A.
Barone, C.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S155 - S155
[25] TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
Garassino, Marina Chiara
Martelli, Olga
Bettini, Anna
Floriani, Irene
Copreni, Elena
Lauricella, Calogero
Ganzinelli, Monica
Marabese, Mirko
Broggini, Massimo
Veronese, Silvio
Gherardi, Giorgio
Longo, Flavia
Fabbri, Maria Agnese
Tomirotti, Maurizio
Alabiso, Oscar
Sarobba, Maria Giuseppa
Labianca, Roberto
Marsoni, Silvia
Farina, Gabriella
Scanni, Alberto
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[26] An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
Huang, Yanping
Cuan, Xiangdan
Zhu, Weiwei
Yang, Xingying
Zhao, Yunli
Sheng, Jun
Zi, Chengting
Wang, Xuanjun
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
[27] ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY
Hernandez, Alba
Calera, Lourdes
Alvarez, Maria
Hernando, Jorge
Torres, Irene
Pajares, Isabel
Madani, Julia
Cebollero, Ana
Anton-Torres, Antonio
Artal, Angel
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1017 - S1017
[28] Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Wang, Fen
Wang, Shuhang
Wang, Zhijie
Duan, Jianchun
An, Tongtong
Zhao, Jun
Bai, Hua
Wang, Jie
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
[29] Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Fen Wang
Shuhang Wang
Zhijie Wang
Jianchun Duan
Tongtong An
Jun Zhao
Hua Bai
Jie Wang
Journal of Experimental & Clinical Cancer Research, 31
[30] To Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC with Wild-Type EGFR
Jiang, D.
Yu, Q.
Zhang, X.
Huang, F.
Li, Y.
Jin, H.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1053 - S1053

← 1 2 3 4 5 →